Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains.
The genetic determinants for the complete Shigella sonnei lipopolysaccharide (LPS) have been cloned, characterized by restriction mapping, and expressed in heterologous genetic backgrounds, including Salmonella typhi and Vibrio cholerae live attenuated vaccine strains. The rfb/rfc locus encoding the polymerized serotype-specific O polysaccharide was mapped within 23 kb of DNA isolated from S. sonnei virulence plasmid pWR105. A highly similar chromosomal DNA sequence was identified by Southern hybridization analysis in Plesiomonas shigelloides known to have the same O serotype specificity as S. sonnei. Expression studies of the rfb/rfc locus have shown that S. sonnei O polysaccharide is covalently bound to LPS cores of both the K-12 and R1 types, but neither to Salmonella (Ra-type) nor to V. cholerae O1 cores. In order to express a compatible core structure in the latter organisms, chromosomal rfa loci encoding R1-type LPS were isolated from both an Escherichia coli R1 strain (rfaR1) and from S. sonnei (rfasonnei). Restriction mapping and functional analysis of cloned DNA allowed us to localize the rfaR1 locus and to orient it with respect to the neighbouring cysE chromosomal marker. A high degree of sequence similarity was found at the DNA level between rfa loci of enterobacterial species characterized by R1-type LPS. Co-expression studies involving S. sonnei rfb/rfc and rfa loci propagated on compatible plasmids have shown that, at most, 13 to 14 kb of rfaR1 DNA are required for the expression of complete phase-I-like S. sonnei LPS in E. coli K-12 and S. typhi, whereas an adjacent region of about 3.5 kb is needed in the more stringent host, V. cholerae. S. sonnei O antigen expressed in a V. cholerae recombinant vaccine strain is present on the cell surface in a form suitable for the induction of a specific antibody response in vaccinated rabbits.
Viret
J F
JF
Swiss Serum and Vaccine Institute, Berne.
Cryz
S J
SJ
Lang
A B
AB
Favre
D
D
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000235:genetics*; D001428:Bacterial Vaccines; D003001:Cloning, Molecular; D004731:Endotoxins / Q000235:genetics*; D004926:Escherichia coli / Q000235:genetics; D005455:Fluorescent Antibody Technique; D015964:Gene Expression Regulation, Bacterial; D005798:Genes, Bacterial; D008070:Lipopolysaccharides / Q000378:metabolism*; D019081:O Antigens; D010957:Plasmids; D011135:Polysaccharides, Bacterial / Q000235:genetics*; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000032:analysis; D012485:Salmonella typhi / Q000235:genetics; D012764:Shigella sonnei / Q000235:genetics*; D013045:Species Specificity; D014611:Vaccination; D014613:Vaccines, Attenuated; D014734:Vibrio cholerae / Q000235:genetics
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D004731:Endotoxins; D008070:Lipopolysaccharides; D019081:O Antigens; D011135:Polysaccharides, Bacterial; D011993:Recombinant Fusion Proteins; D014613:Vaccines, Attenuated